A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)

PHASE3CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

January 21, 2016

Primary Completion Date

April 11, 2018

Study Completion Date

April 11, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

CB-03-01 cream, 1%

CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

DRUG

Vehicle cream

Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

Trial Locations (54)

10549

The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco

11790

DermResearch Center of New York, Inc., Stony Brook

17033

The Pennsylvania State University and the Milton S. Hershey Medical Center, Hershey

23507

Clinical Research Associates of Tidewater, Inc., Norfolk

27157

Wake Forest University Health Sciences, Winston-Salem

27612

Wake Research Associates, Raleigh

29607

Greenville Dermatology, LLC, Greenville

30263

MedaPhase, Inc., Newnan

31038

Site 3804, Kharkiv

33125

Site 0196, Miami

33126

Site 0197, Miami

33135

Site 0198, Miami

33145

Site 0199, Miami

33162

Tory Sullivan, M.D., P.A., North Miami Beach

33172

Site 0191, Miami

Site 0192, Miami

33176

Site 0195, Miami

33434

Site 0190, Boca Raton

33437

Study Protocol, Inc., Boynton Beach

33609

MOORE Clinical Research, Inc., Tampa

33709

Meridien Research, St. Petersburg

37130

International Clinical Research - Tennessee LLC, Murfreesboro

37215

Tennessee Clinical Research Center, Nashville

46006

Site 3803, Ternopil

46032

Site 0152, Carmel

46168

The Indiana Clinical Trials Center, Plainfield

48202

Henry Ford Health System, Detroit

49000

Site 3802, Dnipro

61002

3808, Kharkiv

64506

MediSearch Clinical Trials, Saint Joseph

69063

Site 3809, Zaporizhzhya

72205

Gary M. Petrus, MD PA, Little Rock

77030

The University of Texas Health Science Center at Houston, Houston

77401

Bellaire Dermatology Associates, Bellaire

77845

J&S Studies, Inc., College Station

78660

Austin Institute for Clinical Research, Inc., Pflugerville

78746

Westlake Dermatology Clinical Research Center, Austin

79014

3807, Lviv

80220

Horizons Clinical Research Center, LLC, Denver

90036

Vitiligo & Pigmentation Institute of Southern California, Los Angeles

90404

Clinical Science Institute, Santa Monica

92120

San Diego Sports Medicine and Family Health Center, San Diego

92123

Rady Childrens Hospital, Pediatric and Adolescent Dermatology, San Diego

92701

Southern California Dermatology, Santa Ana

92780

Memorial Research Medical Clinic dba / Orange County Research Center, Tustin

94538

Center For Dermatology Clinical Research, Inc., Fremont

97210

Oregon Dermatology and Research Center, Portland

98101

Dermatology Associates, Seattle

99202

Premier Clinical Research, Spokane

02886

Omega Medical Research, Warwick

0159

Site 9911, Tbilisi

0179

Site 9913, Tbilisi

0194

Site 9912, Tbilisi

01601

Site 3801, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cassiopea SpA

INDUSTRY

NCT02608450 - A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) | Biotech Hunter | Biotech Hunter